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Zinc modulates mononuclear cellular calcitriol metabolism in perito-
neal dialysis patients. Zinc has long been known to play a role in
maintaining immunologic function. Hypozincemia, however, is common in
patients with end-stage renal disease (ESRD) treated with continuous
ambulatory peritoneal dialysis (CAPD). We previously demonstrated that
zinc depletion limits the ability of animals to achieve maximum circulating
calcitriol levels in response to the stress of calcium or phosphorus
depletion. It was unclear, however, whether changes in the circulating
levels of calcitriol in these settings was associated with a direct effect on
renal 1-a hydroxylase activity, or whether the zinc dependence of the
stimulated calcitriol response involved an integrated systemic response in
intact animals. In addition it was unclear whether circulating zinc levels or
zinc nutritional status modified calcitriol metabolism in humans. To better
understand the role zinc plays in the immune response in patients with
ESRD, we studied IL-i, calcitriol and tumor necrosis factor-a production
by mononuclear cells from blood and peritoneal effluents of 22 patients
with ESRD treated with CAPD. Macrophages from peritoneal effluents
and peripheral blood mononuclear cells were isolated and pulsed with
phytohemagglutinin in medium to which different concentrations of zinc
chloride, copper chloride, and carbonyl cyanide p-(trifluoromethoxy)-
phenyl-hydrazone (FCCP), an inhibitor of mitochondrial function were
added. Supernatant interleukin-1, calcitriol, and tumor necrosis factor-a
levels were subsequently measured. We demonstrated a zinc concentra-
tion dependent increase in stimulated IL-la and -13, and TNF-a release in
both peripheral mononuclear cells and peritoneal macrophages from
patients with ESRD treated with CAPD. The effect is zinc specific, as it is
not reproduced by copper or chloride supplementation. A zinc concen-
tration dependent increase in peritoneal macrophage calcitriol release was
also noted. FCCP blocked the cellular production of IL-la, IL-113, and
TNF-a, but had little effect on zinc-induced stimulated mononuclear cell
supernatant calcitriol levels. The different shape of the zinc dose response
curve, and the lack of correlation between paired IL-i and calcitriol
supernatant levels suggests the effect of zinc on mononuclear cellular
cytokine and calcitriol production is mediated through different pathways.
Peritoneal host responses may be an important determinant of
the incidence of peritonitis in patients with end-stage renal
disease (ESRD) treated with continuous ambulatory peritoneal
dialysis (CAPD). Attention has been focused on defects in
intrinsic peritoneal macrophage and cellular responses, due to
variations in ambient pH, glucose concentrations, osmolality of
dialysates and dwell times, and the effect of coexistent conditions
such as the uremic milieu [1].
Immunologic defects in the environment of peritoneal macro-
phages which may affect antibacterial responses have been de-
scribed [1—3]. Macrophages have the ability to 1-hydroxylate 25
OH D3 to produce 1,25 (OH)2 D3, or calcitriol [4, 5], and calcitriol
modulates lymphocyte interleukin (IL)-2 production, and mono-
cytic IL-i RNA expression in CAPD patients [6].
Hypozincemia is common in patients with ESRD [7—9], and in
patients treated with CAPD [9]. Redistribution of zinc from the
extracellular to intracellular fluid, decreased zinc nutritional
intake and intestinal absorption, and hypoalbuminemia may be
factors determining the circulating level of zinc, rather than zinc
loss in dialysis effluents [9, 10]. Nutritional zinc intake is probably
the most important determinant of plasma zinc concentration in
patients with renal disease [9]. Zinc supplementation in hypozin-
cemic patients with ESRD has been shown to modify lymphocyte
and neutrophil responses [11]. We previously demonstrated that
zinc depletion limits the ability of animals to achieve maximum
circulating calcitriol levels in response to the stress of calcium or
phosphorus depletion [12, 131. It was unclear, however, whether
changes in the circulating levels of calcitriol in these settings was
associated with a direct effect on renal i-a hydroxylase activity, or
whether the zinc dependence of the stimulated calcitriol response
involved an integrated systemic response in intact animals.
In preliminary studies, we assessed the effect of extracellular
zinc concentration on IL-i and calcitriol release from peritoneal
macrophages [14]. In order to better understand the role zinc
plays in the immune response in patients with ESRD, we presently
studied IL-i, calcitriol and tumor necrosis factor-a (TNF-a)
production by mononuclear cells from blood and peritoneal
effluents of patients with ESRD treated with CAPD, and assessed
the role of mitochondrial function in their metabolism.
Methods
Patients
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A total of 22 patients with ESRD treated with CAPD partici-
pated in three separate studies after giving informed consent. All
patients had been treated with CAPD for at least two months. No
patient had clinical or laboratory evidence of peritonitis at the
time of evaluation. All patients had simultaneous evaluation of
serum urea and creatinine concentration. Overnight dwells from
CAPD exchanges were used to isolate peritoneal macrophages
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(PM) for evaluation of cellular cytokine production. Five millili-
ters of whole blood were obtained in citrated glass tubes for
isolation of peripheral blood mononuclear cells (PBM) from
patients at the time of collection of peritoneal effluents. Nine
CAPD patients had simultaneous determination of serum urea
nitrogen (SUN), serum creatinine and plasma and peritoneal
effluent zinc concentrations. Eight patients with essential hyper-
tension, untreated with any medication, in the placebo arm of a
drug study had plasma zinc determinations as controls. SUN and
serum creatinine assays were performed in the clinical laboratory
of the George Washington University Medical Center Ambula-
tory Care Center. Determination of plasma and peritoneal efflu-
ent zinc concentration was performed by atomic absorption
spectrophotometry as previously described [10]. The study was
approved by the George Washington University Committee on
Human Research.
Cellular studies
Macrophages from peritoneal effluents were isolated after
centrifugation and separation by density centrifugation on ficoll-
hypaque [15]. Cells were washed in Eagles medium (zinc concen-
tration = 0.3 mg/liter), counted and their viability checked by
Trypan blue exclusion. Mononuclear phagocytic cells were sepa-
rated by exposure to carbonyl iron, and subsequent separation in
a magnetic field. PBM were isolated and evaluated as previously
described [15], simultaneously with collection of peritoneal efflu-
ents. Suspensions of cells were washed, and batches were adjusted
to i05 cell/ml, before pulsing with 50 ig/ml phytohemagglutinin
(PHA). Cells were incubated for 24 hours at 37°C, following which
they were centrifuged, and the supernatants used in a stimulation
assay, as previously described [15]. The cells were examined under
three conditions. Media was supplemented with either no trace
metal (zero), or zinc chloride at concentrations of 0.5, 1.0, or 2.0
mg/liter. When no trace metal was added, unstimulated as well as
PHA-stimulated cellular cytokine production was determined. In
two separate sets of studies only PHA-stimulated cellular cytokine
production was assessed. In the final assessment, media was
supplemented with no trace metal, zinc or copper chloride at
concentrations of 0.5, 1.0, or 2.0 mg/liter. Copper chloride was
employed as a control for both trace metal and chloride ions.
Cytokine determinations
A bioassay for IL-i was employed, as previously described from
our laboratory [15] in the first two phases of the study. In brief, 1
ml of each supernatant was serially diluted, and incubated with 1
x iO CRL 1445 IL-i dependent fibroblasts (ATCC, Rockville,
MD, USA) in culture for 48 hours at 37°C. Target cells were
harvested, counted, and 1 x i0 cells were pulsed in fresh media
with tritiated thymidine for 24 hours at 37°C. The number of cells
per culture was checked using a manual cytometer prior to
harvesting, and the results reported as counts per minute (CPM)
per culture readjusted to 1 x i05 cells. In addition, in the third
phase of the study, IL-ia, IL-j3, and TNF-a were measured by a
commercial ELISA (R and D Systems, Minneapolis MN, USA).
These results are reported in pg/mi supernatant. The lower limit
of detection for the ELISAs was 1 pg/ml. All undetectable levels
were entered as 1 pg/mI for analysis. Measurements were made in
triplicate for each sample in all interleukin and TNF-a assays.
Calcitriol assays
Calcitriol levels in supernatants were measured by adaptation
of previously published techniques [16]. In brief, 1 ml of culture
supernatant was extracted with acetonitrile and washed with a
basic buffer, subjected to sequential silica and C18 mini-column
chromotography, and the 1,25 (OH)2D3 fraction was purified
further using high performance liquid chromatography (HPLC),
as previously described [17]. The HPLC eluate containing the 1,25
(OH)2D3 fraction was measured in triplicate in a radioreceptor
assay, using a binding protein prepared from calf thymus cytosol,
as previously described [12—14, 17]. The lower limit of detection of
the assays utilized in these studies was ito 2 pg/mI. Intraassay and
interassay coefficients of variation were 8 and 14%, respectively,
for the assays utilized in this study.
Inhibition of mitochondrial function
Ten tM/liter carbonyl cyanide p-(trifluoromethoxy)phenyl-hy-
drazone (FCCP) (Sigma Co, St. Louis, MO, USA) added to the
incubation medium, was used as an uncoupler of mitochondrial
oxidative phosphorylation [18].
Data analysis
Data were analyzed by analysis of variance (ANOVA) to
compare mean levels of supernatant cytokines within groups at
different supplemented levels of zinc or copper concentrations.
Differences between mean levels between groups at particular
concentrations of additional zinc or copper were assessed by
ANOVA and confirmed with Fisher's PLSD test. Mean stimu-
lated supernatant cytokine levels in PM and PBM cultures, and
mean stimulated supernatant calcitriol levels in PM exposed and
unexposed to FCCP at similar zinc concentrations were compared
using paired t-tests. Mean stimulated supernatant zinc, copper
and FCCP modified cytokine levels in PM and PBM cultures, both
within groups at different supplemented zinc and chloride con-
centrations, and between the three groups at similarly supple-
mented zinc and chloride concentrations were compared using
ANOVA, followed by confirmation with Fisher's PLSD tests. P <
0.05 was taken as the level of significance. All data are reported as
mean SEM.
Results
Study 1
To determine whether extracellular zinc levels modulate mono-
nuclear cell cytokine production, nine patients with ESRD treated
with CAPD were studied. These subjects also had simultaneous
determination of plasma and peritoneal fluid zinc concentration.
Laboratory values of these patients are provided in Table 1. The
mean plasma zinc concentration in the nine CAPD patients was
2.4 0.1 mg/liter, less than 50% of, and significantly lower (P <
0.0001) than the mean value in the hypertensive controls, 5.8
0.4 mg/liter. Mean peritoneal fluid zinc concentration in the nine
patients was 33 5 big/liter, roughly two orders of magnitude less
than the mean plasma level in this group of patients. Plasma and
peritoneal zinc concentrations, however, were correlated in the
patients (r = 0.69, P < 0.05). There was no correlation between
plasma creatinine and zinc concentrations in these patients. There
was also no correlation between plasma or peritoneal zinc con-
centration with either unstimulated or PHA-stimulated macro-
phage IL-i levels at any concentration of added zinc chloride.
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Patient #
Serum urea
nitrogen mg/c/I
Serum
creatinine
Plasma zinc
mg/liter
Peritoneal fluid
zinc ug/L
1 56 13.7 2.1 30
2 79 10.8 2.3 46
3 66 17.4 2.5 29
4 108 17.0 2.0 13
5 39 17.4 2.8 62
6 75 8.1 2.7 46
7 87 7.5 1.9 13
8 59 19.0 2.6 13
9 65 15.0 2.5 46
The mean unstimulated PM IL-i release, with no additional
zinc added, was 409 24 CPM/culture, and increased 607% after
stimulation with PHA to 2892 321 CPM/culture (P < 0.0001).
The stimulated PM IL-I release increased significantly at each
additional increment of zinc concentration, compared with the
unstimulated value, and between each additional increment of
zinc concentration (P < 0.0001, ANOVA).
Study 2
Study 2 was designed to determine whether differences exist
between PBM and PM IL-i production in response to changes in
extracellular zinc levels, and whether extracellular zinc levels
modulate mononuclear cell calcitriol production in patients
treated with CAPD. In addition, the experiments were designed to
determine whether zinc mediated mononuclear cell calcitriol
production was dependent on mitochondrial function. Twelve
CAPD patients, studied in one session, had simultaneous evalu-
ation of both PBM and PM responses to graded increases in
media zinc concentration. All twelve had mononuclear cell calcit-
riol production, as well as IL-i production evaluated. In this study,
stimulated IL-i levels were employed as a control for level of
mononuclear cell activation [19]. In simultaneous experiments,
FCCP added to the incubation medium was used as an uncoupler
of mitochondrial oxidative phosphorylation [18].
Results of supernatant IL-i level studies in unstimulated and
stimulated PBM cultures were similar to those assessed in PM
cultures. Once again, there was a zinc dependent, monotonic
increase in IL-i levels at each additional incremental level of
added zinc concentration (Fig. 1). Both PBM and PM IL-i levels
at each different zinc concentration were different from all other
determinations (P < 0.0001, ANOVA). Stimulated PBM IL-i
levels were greater than PM IL-i levels at each zinc concentration
studied (P = 0.0001; Fig. 1). There was no correlation between
patients' plasma zinc concentration and stimulated cellular super-
natant IL-i levels in any assessment.
Mean stimulated PM supernatant calcitriol concentration, with-
out the addition of zinc was 225 4i pg/ml. The stimulated PM
supernatant calcitriol concentration increased approximately 3.5-
fold at 1.0 and 2.0 mg/liter zinc concentration, compared with the
level when zinc was not added (P < 0.03, ANOVA; Fig. 2). In
contrast to the findings when IL-i was evaluated, in which a
monotonically increasing level of IL-i release was seen with each
incremental addition of zinc chloride in PM or PBM cultures,
there was no difference between stimulated PM supernatant
calcitriol levels when assessed at zinc concentrations of 1.0 and 2.0
mg/liter (Fig. 2). Stimulated supernatant IL-i and calcitriol levels
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Fig. 1. Peripheral blood mononuclear cell (PBM) (circles) and peritoneal
macrophage (PM) (squares) supernatant IL-i levels as a function of added
extracellular zinc concentration in unstimulated and P1-IA-stimulated condi-
tions. PHA stimulated cells were studied at different zinc media concen-
trations (no additional zinc chloride = zero, and 0.5, 1.0 and 2.0 mg/liter
added zinc chloride). There was a monotonically increasing level of
supernatant IL-i at each level of added zinc in both PBM and PM
(ANOVA, P < 0.0001). In stimulated conditions, PBM IL-i supernatant
levels were always greater than PM levels at any individual level of added
zinc concentration (P = 0.0001).
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Fig. 2. Peritoneal macrophage supematant calcitriol levels in PHA-stimu-
lated conditions. P1-IA stimulated cells were studied at different zinc media
concentrations (no additional zinc chloride = zero, and 0.5, 1.0 and 2.0
mg/liter added zinc chloride). There was a zinc dependent increase in
supernatant calcitriol levels at 1.0 and 2.0 mg/liter zinc, compared with the
case of no additional zinc (ANOVA, P < 0.03).
were not correlated, nor was there a correlation of patients'
plasma zinc and stimulated cellular calcitriol supernatant levels in
any assessment.
The addition of FCCP to medium with different concentrations
of supplemental zinc chloride did not diminish supernatant cal-
citriol levels, although it abolished the zinc-mediated increase in
supernatant calcitriol levels (Fig. 3). Supernatant calcitriol levels
were higher in the baseline condition without added zinc or FCCP
(623 120 vs. 207 35 pglml, P < 0.01). There was, however, no
difference between mean supernatant calcitriol levels in cell
cultures treated with and without FCCP, at added zinc concen-
trations of 0.5, 1.0, and 2.0 mg/ml (Fig. 3).
Study 3
This study was designed to determine whether the zinc medi-
ated effects were trace metal specific, and to assess the role of
Table 1. Solute levels in study patients
Unstimulated 0.0 0.5 1.0 1.5 2.0
Added zinc concentration, mg/liter
0
C)
0
800
600
400
200
0
1410 Kimmel et al: Zinc and peritoneal dialysis
1600
1400
1200
1000
800
600
400
200
0
Added zinc concentration, mg/liter
Fig. 3. Peritoneal macrophage supernatant calcitriol levels in PHA-stimu-
lated conditions. PHA stimulated cells were studied at different zinc media
concentrations (no additional zinc chloride = zero, and 0.5, 1.0 and 2.0
mg/liter added zinc chloride), in the presence and absence of 10 jsm/liter
FCCP, an inhibitor of mitochondrial function. There was a zinc dependent
increase in supernatant calcitriol levels at 1.0 and 2.0 mg/L zinc, compared
with the case of no additional zinc, in the absence of FCCP (squares).
Mean supernatant calcitriol levels were greater in cultures with additional
FCCP (circles), in the absence of added zinc chloride, but there was no
change in calcitriol levels in the presence of additional zinc chloride
(ANOVA). There was also no difference between supernatant calcitriol
levels at any level of supplemental zinc in cells exposed and unexposed to
FCCP.
chloride ion by using copper chloride as a trace metal control. In
addition, the experiments were designed to determine whether
zinc mediated cytokine production and release was dependent on
mitochondrial function. Twenty-two patients had PM and PBM
cell stimulated superriatant IL-la and -13, and TNF-a levels
evaluated in media with different zinc and copper chloride
concentrations. In simultaneous experiments, FCCP was used as
an inhibitor of mitochondrial function. Mean PHA-stimulated
PM supernatant IL-la concentration, with no additional zinc
added, was 10.5 1.1 pg/mI. PM supernatant IL-la levels
increased significantly at each additional increment of zinc con-
centration, compared with baseline and with each additional
increment of zinc concentration (P < 0.0001, ANOVA; Fig. 4).
Although baseline response was similar to that of the zinc treated
cells, there was no effect of increasing the concentration of copper
chloride on PHA stimulated PM supernatant IL-la level in the
absence of supplemental zinc chloride (Fig. 4). The addition of
FCCP to PM treated with zinc resulted in the abolition of the
zinc-induced increase in supernatant IL-la levels. Supernatant
IL-I a levels in PM exposed to FCCP were all similar, but all lower
than the mean P1-IA-stimulated PM supernatant IL-la concen-
tration, with no additional zinc added (P < 0.000 1, ANOVA; Fig.
4). There was no difference between supernatant IL-la levels in
PM exposed to zinc or copper at a concentration of 0.5 mg/liter;
however, there were differences between all three groups at zinc
or copper concentrations of 1 and 2 mg/liter. The interassay and
intraassay coefficients of variation for this IL-la assay were 6.9
and 7.4%, respectively. Similar responses were noted regarding
stimulated PM IL-113 (Fig. 5) and TNF-a (Fig. 6) supernatant
concentration in cultured cells treated with zinc, copper, and zinc
plus FCCP, except there were differences between all three groups
at each different concentration of supplemental zinc or copper in
these studies (P < 0.0001, ANOVA). The interassay and intraas-
say coefficients of variation for this IL-lp and TNF-a assay were
Added zinc or copper concentration, mg/liter
Fig. 4. Peritoneal macrophage supernatant IL-la concentration as a func-
tion of added extracellular zinc concentration. PHA stimulated cells were
studied at different zinc media concentrations (no additional zinc chloride
= zero, and 0.5, 1.0 and 2.0 mg/liter added zinc chloride), with (triangles)
and without (circles) the addition of FCCP. Simultaneous experiments
substituted addition of copper chloride rather than zinc chloride at 0.5, 1.0
and 2.0 mg/liter, as a control for the effect of both the trace metal and the
chloride ion (squares), in the absence of FCCP. There was a monotoni-
cally increasing level of supernatant IL-la at each level of added zinc, in
the absence of FCCP (P = 0.0001, ANOVA). There was no effect of
additional copper chloride on supernatant IL-la levels. The addition of
FCCP markedly reduced supernatant IL-la levels (P = 0.0001, ANOVA).
Fig. 5. Peritoneal macrophage IL-i 13 supernatant concentration as a func-
tion of added extracellular zinc concentration. PHA stimulated cells were
studied at different zinc media concentrations (no additional zinc chloride
= zero, and 0.5, 1.0 and 2.0 mg/liter added zinc chloride), with (triangles)
and without (circles) the addition of FCCP. Simultaneous experiments
substituted addition of copper chloride rather than zinc chloride at 0.5, 1.0
and 2.0 mg/liter, as a control for the effect of both the trace metal and the
chloride ion (squares), in the absence of FCCP. There was a monotoni-
cally increasing level of supernatant IL-ip at each level of added zinc, in
the absence of FCCP (P = 0.0001, ANOVA). There was no effect of
additional copper chloride on supernatant IL-1f3 levels. The addition of
FCCP markedly reduced supernatant IL-1/3 levels (P = 0.0001, ANOVA).
8.2 and 8.8%, and 8.3 and 7.6%, respectively. A similar zinc-
induced increase of IL-la, IL-1/3, and TNF-a was noted in PBM
(data not shown). Addition of copper chloride had no effect on
PHA-stimulated PBM cytokine levels, but the zinc-induced in-
crease in supernatant IL-la, IL-1f3, and TNF-a concentrations
was completely abolished by the addition of FCCP to the medium.
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with renal disease. We, however, demonstrated a zinc concentra-
tion dependent increase in stimulated IL-la and -/3, and TNF-a
release in both peripheral blood mononuclear cells and peritoneal
macrophages from patients with ESRD treated with CAPD. The
effect noted is zinc specific, as it is not reproduced by copper or
chloride supplementation. There was, however, no correlation
between patients' plasma and peritoneal zinc levels and cytokine
biology in this in vitro study. This is not surprising since the cells
were washed and placed in culture medium before supernatants
were sampled. Such an effect on mononuclear cell biology is
consistent with the well known effects of zinc as a cofactor for
activation of various enzymes, and described roles of zinc in
transcription and translation [26, 27].
We were able to extend these findings to another monokine,
calcitriol. We have shown a zinc concentration dependent in-
crease in peritoneal macrophage calcitriol release. Clinically in
humans, parathyroid hormone and phosphorus nutritional status
are the most important determinants of renal 1-a hydroxylase
activity and therefore of circulating calcitriol levels [4]. Other
hormones and changes in extracellular ion levels may also mod-
ulate the response of calcitriol to physiological stressors [4]. A
change in zinc nutritional status might conceivably alter such
factors. Our data, however, are consistent with a direct effect of
zinc to modulate extrarenal cellular 1-a hydroxylase activity.
FCCP, an inhibitor of mitochondrial respiration, blocked the
cellular production of IL-la, IL-1f3, and TNF-a, but had little
effect on zinc-induced stimulated mononuclear cell calcitriol
production. The different shape of the zinc dose response curve,
and the lack of correlation between paired IL-i and calcitriol
supernatant levels also suggests the effect of zinc on cellular
Discussion cytokine and calcitriol production is mediated through different
pathways. The relative lack of FCCP inhibition of calcitriol
production is consistent with the continued synthesis and/or
release of calcitriol synthesized in mononuclear cells, specifically
in response to an increase in extracellular zinc concentration,
despite the presence of impaired mitochondrial function. The
differences between the responses of the interleukins and TNF-a,
and calcitriol are consistent with the hypothesis that metabolism
of IL-i and TNF-a may be more dependent on mitochondrial
respiration compared with calcitriol in such cells. It is possible that
changes in extracellular zinc concentration mediate changes in
calcitriol release through changes in distinct zinc-dependent sig-
nal transduction pathways, or by altering the intracellular level of
other ions, such as cytosolic or mitochondrial calcium concentra-
tions. Alternatively, it is possible that FCCP may also have an
effect on the release of cytokines, but not calcitriol, manifest in the
presence of zinc. Finally, it is possible that zinc-induced synthesis
of calcitriol by peritoneal macrophages is mediated by a non-
mitochondrial hydroxylase, as is the case recently described in
another extrarenal tissue [28]. The mechanism of the differential
effects of FCCP on these monokines, however, remains unknown
and must be addressed in further studies.
In an animal model, plasma zinc concentration in uremic
subjects is dependent on nutritional zinc intake [10]. Plasma and
peritoneal fluid concentrations of zinc were correlated in our
patients, and were related presumably to zinc nutritional intake.
Since increases in ambient zinc concentration are associated with
increased cellular cytokine production and modulation of cellular
immunity in patients with ESRD [11, 29—31], and IL-i and other
monokines play a key role in the early response to presented
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Fig. 6. Peritoneal macrophage TNF-cx supernatant concentration as a func-
tion of added extracellular zinc concentration. PHA stimulated cells were
studied at different zinc media concentrations (no additional zinc chloride
= zero, and 0.5, 1.0 and 2.0 mg/liter added zinc chloride), with (triangles)
and without (circles) the addition of FCCP. Simultaneous experiments
substituted addition of copper chloride rather than zinc chloride at 0.5, 1.0
and 2.0 mg/liter, as a control for the effect of both the trace metal and the
chloride ion (squares), in the absence of FCCP. There was a monotoni-
cally increasing level of supernatant TNF-a at each level of added zinc, in
the absence of FCCP (P = 0.0001, ANOVA). There was no effect of
additional copper chloride on supernatant TNF-c.s levels. The addition of
FCCP markedly reduced supernatant TNF-a levels (P = 0.0001,
ANOVA).
Our initial studies in an animal model suggested that the
physiologic increase in calcitriol levels, in response to the stress of
phosphorus or calcium depletion, was limited by nutritional zinc
depletion [12, 13]. Zinc depletion is a common concomitant of
renal insufficiency in patients with renal disease [7—9] and ESRD
treated with CAPD [9, 20]. Mahajan et al [21] showed hypozin-
cemia was present in patients treated with intermittent peritoneal
dialysis, a finding later confirmed in patients treated with CAPD
[20]. It is unclear how much of the diminution in circulating
calcitriol levels in patients with ESRD treated with CAPD is a
result of zinc deficiency [6, 9]. It was also uncertain whether the
diminution of circulating calcitriol levels was a result of an effect
on the action of hormones involved in the control of calcitriol
metabolism or a direct effect of zinc on 1-a hydroxylase synthesis
or activity [4, 9, 12, 13, 22]. To address such issues, we used a
cellular system to assess the effect of extracellular zinc on mono-
nuclear cell calcitriol production.
Previous studies demonstrated a zinc dependent increase in
IL-1f3 and TNF-a production in human peripheral blood mono-
nuclear cells [23, 24]. Goode et a!, however, were unable to show
an increase in culture supernatant IL-1/3 levels from mononuclear
cells from patients with Crohn's disease [25]. Scuderi [23], in
contrast to our findings, noted a copper dependent increase in
supernatant TNF-a levels, but like Driessen et a! [24] and us,
showed copper had no, or a slightly inhibitory effect on IL-1/3
release. These differences may be a consequence of the doses of
zinc and copper employed in the studies, a result of the use of
lipopolysaccharide instead of PHA to stimulate mononuclear
cells, or a result of our use of cells from a population of patients
1412 Kimmel et al: Zinc and peritoneal dialysis
antigens, it is reasonable to assume that zinc nutritional intake
may be an important determinant of the incidence of peritonitis,
infection and other immunologically related responses in patients
with ESRD treated with CAPD. Calcitriol may also modulate
granulocyte and immune cell function [6, 32, 33]. If local tissue
and extracellular calcitriol levels are, at least in part, zinc depen-
dent, changes in extracellular zinc levels and zinc nutritional status
may therefore modulate immune function at several levels. If
initial evidence suggesting calcitriol may be a factor in modulating
intestinal zinc absorption in humans with ESRD is correct [re-
viewed in 9], zinc depletion in such patients could initiate a vicious
cycle of calcitriol deficiency and subsequent immunologic impair-
ment. We did not specifically assess the relationship of cellular
cytokine metabolism to peritonitis rates in this small number of
patients. Further studies to correlate nutritional status and infor-
mation from zinc repletion studies with cellular responses and
epidemiologic data on infection rates, and on the response to
physiologic mediators of calcitriol synthesis are necessary to
confirm such hypotheses. In addition, carefully conducted balance
and electrolyte studies in humans are necessary to establish
whether zinc nutritional status or extracellular zinc concentration
play a physiologic role in the control of calcitriol metabolism in
health and disease. If such a role is established, these and
biochemical and molecular biologic studies will be necessary to
determine the locus of interaction of zinc in the parathyroid-renal
axis.
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